Autoimmune Disease Diagnostics Market Size, Share, Growth, and Industry Analysis, By Type (Analyzers,Assay Kits), By Application (Application), Regional Insights and Forecast to 2033

Autoimmune Disease Diagnostics Market Overview

The Autoimmune Disease Diagnostics Market size was valued at USD 5663.02 million in 2024 and is expected to reach USD 8556.95 million by 2033, growing at a CAGR of 4.7% from 2025 to 2033.

The autoimmune disease diagnostics market has been gaining momentum due to the rising incidence of autoimmune disorders worldwide. As of 2024, more than 80 autoimmune diseases have been identified, affecting approximately 300 million people globally. Among these, conditions such as rheumatoid arthritis, lupus, type 1 diabetes, and multiple sclerosis are the most prevalent. Over 50 million individuals in the United States alone suffer from autoimmune conditions, creating a substantial demand for diagnostic solutions.

The frequency of early-stage screenings has increased, with more than 65% of autoimmune patients now being diagnosed during the first two years of symptom onset. Enhanced awareness, coupled with government support for early detection programs, has driven the number of diagnostic tests performed annually to surpass 200 million worldwide. The integration of molecular diagnostics and immunoassays has significantly improved the accuracy of autoimmune diagnostics. The global use of ELISA-based tests in autoimmune diagnostics exceeded 75 million units in 2023, reinforcing the market’s reliance on immunoassay platforms. Technological advancements, automation of laboratory procedures, and demand for personalized treatment plans continue to drive growth in autoimmune disease diagnostics across healthcare settings.

Key Findings

Top Driver reason: Increasing global prevalence of autoimmune diseases requiring early and accurate diagnostics.

Top Country/Region: North America holds the highest share due to its advanced healthcare infrastructure and high testing frequency.

Top Segment: Assay kits lead due to their widespread use in hospital laboratories and diagnostic centers.

Autoimmune Disease Diagnostics Market Trends

The autoimmune disease diagnostics market is experiencing a shift toward more advanced, accurate, and non-invasive testing methods. Over 42% of autoimmune diagnostics now utilize molecular techniques, including PCR-based assays and next-generation sequencing. The trend toward early-stage disease detection has intensified, with autoantibody testing becoming routine for at-risk populations. In 2023, more than 180 million autoantibody tests were conducted globally, a rise of 12% from the previous year. The increasing use of multiplex immunoassay platforms has allowed clinicians to test for multiple antibodies simultaneously, reducing turnaround time by over 35%.

Automation in diagnostic laboratories has become another key trend. Approximately 68% of hospital labs in developed nations now use automated analysers for autoimmune testing, enabling faster throughput and minimizing human error. Point-of-care testing (POCT) has also gained traction, especially in rural and home-based care settings. In 2023, POCT kits for autoimmune markers accounted for 14% of all diagnostic test sales, up from 9% in 2021. The use of biomarkers in disease staging and progression monitoring is increasing, with over 55 biomarkers currently validated for autoimmune conditions such as systemic lupus erythematosus and Sjögren’s syndrome.

Digital integration and data analytics are being adopted to enhance diagnostic accuracy. AI-assisted platforms for autoimmune diagnosis have been implemented in over 500 medical institutions globally, reducing diagnostic errors by 20% and improving pattern recognition in complex cases. The trend of telepathology and remote diagnostic services has also expanded, with over 25% of test interpretations in 2024 occurring off-site via digital platforms.

Autoimmune Disease Diagnostics Market Dynamics

DRIVER

Increasing global prevalence of autoimmune conditions.

Autoimmune diseases are on the rise globally, affecting more than 300 million people, with an average annual increase of 6–7 million new cases. Conditions like rheumatoid arthritis impact 1 in every 100 individuals globally, while type 1 diabetes affects approximately 9 million people. This growing disease burden necessitates early and precise diagnostics to manage chronic conditions. Hospitals and diagnostic centre’s conducted over 200 million autoimmune-related tests in 2023, with rheumatoid factor and ANA tests leading in volume. The shift toward proactive health management and preventative diagnostics, particularly in developed countries, has resulted in over 65% of new patients being diagnosed through routine screening rather than symptomatic visits.

RESTRAINT

High cost and complexity of diagnostic procedures.

Advanced diagnostic tests for autoimmune diseases, such as immunoblotting and immunofluorescence, often require expensive reagents and trained personnel. The average cost of a comprehensive autoimmune panel exceeds $500 in many healthcare systems, limiting accessibility for uninsured or low-income populations. Over 40% of patients in developing regions report diagnostic delays of more than six months due to affordability and limited test availability. Additionally, certain tests have false-positive rates exceeding 10%, requiring multiple follow-up procedures. The need for specialized labs and equipment restricts market penetration in low-resource settings, where only 28% of hospitals in sub-Saharan Africa are equipped with autoimmune testing capabilities.

OPPORTUNITY

Technological innovation in personalized diagnostics.

Personalized diagnostic platforms that use patient-specific data and biomarkers are gaining attention. Over 1,000 clinical trials related to autoimmune diagnostics and biomarkers are ongoing globally. Technologies like next-generation sequencing and proteomics are being used to profile patient immune responses, identifying disease triggers and predicting flare-ups. Over 70 hospitals in Europe now use personalized diagnostics in autoimmune treatment planning, with customized antibody panels increasing detection accuracy by 25%. The rising interest in pharmacogenomics, which assesses genetic responses to autoimmune drugs, is creating demand for companion diagnostics. Additionally, home testing kits and app-connected diagnostic tools have begun penetrating consumer markets, especially among patients managing long-term autoimmune conditions.

CHALLENGE

Diagnostic overlap and limited disease-specific markers.

One of the primary challenges in autoimmune disease diagnostics is the overlap of symptoms among various disorders. For example, over 30% of patients with lupus also present symptoms common to rheumatoid arthritis, complicating diagnosis. Moreover, certain autoimmune diseases lack disease-specific markers, leading to inconclusive results. In more than 20% of cases involving early-stage autoimmune conditions, current diagnostics fail to deliver a definitive diagnosis, requiring repeated testing over several months. This diagnostic ambiguity affects patient treatment plans and increases healthcare costs. In addition, limited access to AI-integrated diagnostics in developing markets hinders the broader adoption of precision diagnostic tools.

Autoimmune Disease Diagnostics Market Segmentation

The autoimmune disease diagnostics market is segmented by type and application. Type segmentation includes analysers and assay kits, while application includes hospitals and research laboratories. The growing preference for rapid and accurate testing kits supports higher growth in the assay kits segment, whereas analysers are increasingly integrated into automated laboratory systems.

By Type

Analyzers: Analysers play a crucial role in centralized diagnostic labs and hospital settings. More than 65% of large hospitals use automated immunoanalyzers for ANA, ENA, and other autoimmune testing. These systems offer high throughput, with some machines processing over 200 samples per hour. As of 2023, approximately 14,000 immunoassay analysers were in active use globally. The need for reduced human error and quicker result turnaround is driving their adoption, particularly in reference laboratories and high-volume testing centers.

Assay Kits: Assay kits represent over 70% of test volume globally due to their versatility, affordability, and ease of use. Over 100 million assay kits for ANA, rheumatoid factor, and anti-CCP were sold in 2023. Hospitals and clinics prefer ELISA-based and chemiluminescence-based kits due to their standardized formats and compatibility with multiple platforms. The emergence of multiplexed kits that allow simultaneous testing for multiple autoimmune markers has further accelerated usage.

By Application

Hospitals: Hospitals perform the bulk of autoimmune diagnostic testing, accounting for over 60% of market usage. Tertiary care hospitals frequently conduct advanced diagnostic panels to support treatment for complex autoimmune diseases such as multiple sclerosis and vasculitis. More than 80% of rheumatology departments globally are equipped with immunoassay platforms.

Research Laboratories: Research institutions account for approximately 15% of total diagnostic volumes. These facilities are involved in biomarker discovery, assay development, and validation of diagnostic methodologies. In 2023, over 350 autoimmune-focused research labs globally engaged in developing novel biomarkers and diagnostic tools to enhance disease stratification and treatment monitoring.

Autoimmune Disease Diagnostics Market Regional Outlook

• North America

remains the most dominant region in the autoimmune disease diagnostics market. The U.S. alone contributes to over 45% of all global autoimmune testing volume. In 2023, over 125 million autoimmune diagnostic tests were conducted in the U.S., with rheumatoid arthritis, type 1 diabetes, and lupus being the most frequently tested diseases. Over 90% of hospitals in Canada and the U.S. use immunoassay-based diagnostics for autoimmune disorders.

• Europe

is the second largest region, led by countries such as Germany, France, and the UK. Germany has over 600 labs specializing in autoimmune diagnostics, while France has implemented national screening programs for autoimmune thyroiditis and lupus, covering over 15 million people. The European Commission’s investment in research and development exceeded €1.2 billion between 2022 and 2024, supporting new diagnostic technologies.

• Asia-Pacific

It is witnessing significant growth due to increased healthcare access and disease awareness. In India, autoimmune diseases affect more than 20 million people, while in China the figure exceeds 35 million. Both countries have increased their national diagnostic capacity, with over 2,500 new diagnostic labs opened in the past three years. Japan’s robust healthcare system ensures more than 90% diagnostic coverage for common autoimmune conditions.

• Middle East & Africa

Diagnostic capabilities remain limited but are improving. Saudi Arabia and the UAE have invested in hospital automation, equipping over 300 facilities with immunodiagnostic systems. However, more than 60% of countries in sub-Saharan Africa still rely on basic bloodwork and symptom observation for autoimmune diagnosis, with limited availability of specialized assays.

List of Top Autoimmune Disease Diagnostics Companies

• Abbott Laboratories
• Beckman Coulter
• Bio-Rad Laboratories
• EUROIMMUN
• Inova Diagnostics
• Roche Diagnostics
• Siemens Healthcare
• DiaSorin
• ERBA Diagnostics
• Euro Diagnostica
• Autoimmune Technologies
• Avant Diagnostics
• Exagen Diagnostics
• Gold Standard Diagnostics
• HOB Diagnostics
• HUMAN Diagnostics
• Immco Diagnostics
• ImmunArray
• Myriad Genetics
• Omega Diagnostics
• ORGENTEC Diagnostika
• Phadia
• Protagen

Top Two Companies with the Highest Share

Roche Diagnostics: holds one of the largest shares in the autoimmune disease diagnostics market with over 150 million diagnostic tests performed using its systems annually.

Abbott Laboratories: follows closely with wide global reach and over 100 autoantibody assay kits in circulation, supporting diagnostic workflows in more than 10,000 laboratories.

Investment Analysis and Opportunities

Global investment in autoimmune disease diagnostics exceeded $9 billion in 2023, driven by increased healthcare spending and growing emphasis on early disease detection. Private equity and venture capital funding focused heavily on assay development, personalized diagnostics, and AI-assisted testing platforms. More than 600 startups globally are innovating in this space, with over $1.5 billion raised in seed and Series A rounds alone.

Government support continues to be significant. For example, the U.S. National Institutes of Health allocated over $750 million in 2023 for autoimmune diagnostics research. In the EU, Horizon Europe committed €500 million toward biomarker discovery and test development. Investments are particularly focused on multiplexed and rapid diagnostic kits, capable of delivering results in under 30 minutes.

There is also growing interest in developing diagnostics suitable for point-of-care and home use. Over 50 companies launched portable autoimmune test kits in 2023, targeting conditions such as celiac disease and thyroiditis. Hospitals are upgrading laboratory infrastructure to integrate high-throughput analyzers, supported by investments from both public and private sectors.

Emerging markets such as Brazil, South Africa, and Southeast Asia are being targeted for market expansion, with investments in localized manufacturing and training programs. Several public-private partnerships have emerged in these regions to improve access to diagnostic services, with over 700 facilities upgraded since 2022 through such collaborations.

New Product Development

Innovation in autoimmune disease diagnostics is centred around rapid testing, biomarker discovery, and integration with digital health systems. In 2023 alone, over 1,200 new diagnostic products were introduced globally, with a strong focus on multiplex assays and microfluidic-based devices.

One of the most notable innovations includes biochip array technology, which allows simultaneous testing of up to 20 autoantibodies on a single platform. More than 100 hospitals in Europe have adopted this system, cutting diagnostic time by 50%. Portable biosensors connected to mobile apps have been developed for self-monitoring of autoimmune thyroid conditions, with over 50,000 units sold in pilot markets.

AI-powered platforms that assist in interpreting immunofluorescence patterns are now being deployed in diagnostic labs, improving accuracy and reducing diagnostic ambiguity by 25%. Advanced ELISA kits with enhanced specificity and sensitivity were released by several manufacturers in 2024, demonstrating over 95% accuracy for early-stage lupus detection.

Companies are also introducing companion diagnostic kits that support personalized medicine. For example, a newly launched anti-IL-6 companion test is now used alongside biologic therapies in rheumatoid arthritis patients, guiding treatment in over 10,000 patients globally.

Five Recent Developments

• Roche Diagnostics introduced a high-throughput immunoassay platform capable of processing 500 autoimmune samples per hour across 200 labs worldwide.
• Abbott Laboratories launched a home-based celiac disease testing kit in 2024, approved for over-the-counter use and sold in over 25 countries.
• Bio-Rad Laboratories announced an advanced ANA multiplex assay in early 2024, achieving 98% diagnostic accuracy across clinical trials.
• EUROIMMUN expanded its AI-enhanced pattern recognition software for IFA testing in 2023, deployed in over 800 laboratories globally.
• Exagen Diagnostics partnered with 20 rheumatology clinics in 2024 to pilot its personalized lupus flare predictor using a biomarker-based algorithm.

Report Coverage of Autoimmune Disease Diagnostics Market

The report on the autoimmune disease diagnostics market offers comprehensive insight into diagnostic technologies, application settings, regional performances, and emerging innovations. It covers over 50 autoimmune conditions with active diagnostic demand, including rheumatoid arthritis, lupus, Sjögren’s syndrome, and autoimmune thyroiditis. The report includes detailed segmentation by type, assay methodology, disease target, and diagnostic setting, supported by over 350 data tables and market visuals.

Geographic analysis spans more than 25 countries, highlighting test volumes, healthcare access, and infrastructure readiness. Clinical workflow analysis provides insight into test preference, laboratory automation trends, and turnaround times. The report evaluates more than 40 major manufacturers and over 200 emerging firms engaged in autoimmune diagnostics.

Market coverage extends to assay performance benchmarks, reimbursement policy comparisons, regulatory pathways, and trends in biomarker validation. It includes investment flows, partnership developments, and technology licensing data from 2020 through 2024. Emerging technologies, such as AI interpretation platforms, companion diagnostics, and home testing kits, are thoroughly examined.

The report supports strategic decision-making for investors, diagnostic companies, hospitals, and research institutions by offering actionable data and market forecasting across the autoimmune disease diagnostics ecosystem.

Frequently Asked Questions